Latest News

(UroToday.com) Beginning with the introduction of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2004, there has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer including a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), second-line chemotherapy (cabazitaxel), bone-targeting agents (radium-223) and other targeted agents (including olaparib, rucaparib, […]

(UroToday.com) The Breaking Barriers session ensuring equity in cancer diagnosis, treatment, and trial enrollment for patients with kidney and bladder cancer included a discussion regarding a patient’s perspective of barriers to best care from Bladder Cancer Advocacy Network and SWOG patient advocate Mr. Rick Bangs.

(UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor with a long half-life that is an effective treatment option for patients with previously treated metastatic renal cell carcinoma (RCC). In the phase 3 TIVO-3 trial, tivozanib demonstrated favorable tolerability and statistically significant improvement in progression free survival (PFS; median PFS 5.6 versus […]

(UroToday.com) The 2021 ASCO annual meeting’s poster discussion session for prostate cancer included a discussant presentation by Dr. Julie Graff discussing novel approaches to metastatic prostate cancer. Dr. Graff notes that over the last decade we have made significant strides in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with several new agents available, relying heavily […]

(UroToday.com)  Antibodies and small molecule ligands target PSMA with different kinetics and biodistribution, with certain sites of PSMA expression such as salivary/lacrimal glands, kidneys, and small bowel less accessible to large antibodies. Alpha emitters such as 225Ac have high potency, but short range; 225Ac-J591 has previously completed radiochemistry and xenograft studies. At the 2021 ASCO virtual […]

(UroToday.com) Radiation toxicity is defined as the transient or long-term sequelae to normal tissues due to pelvic radiotherapy. The most common pelvic radiation toxicity is gastrointestinal, and it is estimated that 10-20% of patients may develop GI toxicities over a ten-year period following pelvic radiation. Diarrhea, bleeding, and incontinence are the most common GI toxicities, with […]

(UroToday.com) While more patients are surviving their pelvic cancers, unfortunately, the ability to prevent long-term sequelae of pelvic radiation lags behind this improvement in survival. Later side effects from pelvic radiation can manifest months to years after therapy to reduce quality of life and cause psychological morbidity. How best to optimize cancer survivorship care in the […]

(UroToday.com) In this presentation, Eden Stotsky-Himelfarb, RN, shared her personal story of being diagnosed with a pelvic cancer at a young age that required treatment with radiation and chemotherapy, and the significant impact this had on her life subsequently.

(UroToday.com)  While there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years, these studies have focused on patients with clear cell histology. As a result, there have been little direct data to guide care for patients with non-clear cell histologies and we have had to […]

(UroToday.com)  There have been transformational changes in first-line therapy for patients with metastatic renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations […]